ICD-10 code C33: Malignant neoplasm of trachea

Key Takeaways

ICD-10 code C33 is the billable ICD-10-CM diagnosis code for malignant neoplasm of trachea (primary tracheal cancer), valid for FY 2026.

C33 is accepted for all HIPAA-covered transactions and is covered by Medicare; it falls within the C30-C39 respiratory malignancy block.

Tracheal cancer is rare, representing less than 1% of all respiratory malignancies, making precise documentation critical to support C33 over adjacent codes like C34.

Pabau’s claims management software validates ICD-10-CM codes at point of entry, reducing C33 claim denials caused by missing laterality or staging documentation.

ICD-10 code C33 is the billable ICD-10-CM code for malignant neoplasm of the trachea, a rare cancer that begins in the windpipe itself rather than the bronchi or lungs. Correctly assigning it depends on documenting exactly where the tumor sits relative to the carina, the anatomical line that separates C33 from the neighboring C34 code.

This guide covers C33’s billable status, coding guidelines, MS-DRG mapping, and how it differs from the surrounding respiratory codes for FY2026 claims.

ICD-10 code C33: definition and billable status

ICD-10 code C33 is the valid, billable ICD-10-CM diagnosis code for malignant neoplasm of trachea. It is current for the fiscal year 2026 and is accepted for all HIPAA-compliant claim submission workflows across inpatient and outpatient settings.

The code belongs to the C30-C39 block (malignant neoplasms of respiratory and intrathoracic organs) within chapter C00-D49 of the ICD-10-CM tabular list. As confirmed by the CMS ICD-10 codes resource, C33 carries no fifth-character subdivisions: it is a single, non-further-specified code with no child codes beneath it.

Clinical description: What is malignant neoplasm of trachea?

The trachea is the cartilaginous tube (the windpipe) that connects the larynx to the bronchi, carrying air into and out of the lungs. A malignant neoplasm of the trachea is a primary cancer arising from the tracheal wall itself, as distinct from cancers that invade the trachea secondarily from adjacent structures such as the thyroid or esophagus.

Tracheal cancer is rare. According to the WHO ICD-10 classification, tracheal malignancies account for less than 1% of all respiratory tract cancers. Squamous cell carcinoma and adenoid cystic carcinoma are the two most common histological subtypes, though C33 does not specify histology: a separate morphology code from the M-code series would accompany C33 in a complete diagnosis.

For coders, the distinction between a primary malignant neoplasm originating in the tracheal epithelium and a secondary (metastatic) involvement of the trachea is critical. C33 encodes primary tracheal malignancy only. Secondary involvement is coded with a metastatic site code from the C77-C79 range plus a separate code identifying the primary site — for example, a malignant neoplasm of the rectum (C20) that has metastasized to the trachea.

Synonyms and applicable to notes

The ICD-10-CM tabular list carries an “Applicable To” note for C33 that defines the scope of the code. Coders working from operative reports, pathology notes, or physician diagnoses using any of the following phrases may assign C33:

• Primary malignant neoplasm of trachea
• Malignant neoplasm of trachea
• Tracheal cancer (primary)
• Tracheal carcinoma (primary)
• Tracheal malignancy

These are approximate synonyms recognized under the same ICD-10-CM conventions that govern other narrowly defined codes, such as Z90.3. The “Includes” note at the top of the C30-C39 block also states that the range covers primary malignant neoplasms of the stated or implied sites, so documentation phrased as “carcinoma of trachea” without a laterality qualifier still maps to C33.

What C33 does not cover: secondary (metastatic) neoplasms of the trachea, benign tracheal neoplasms (D14.2), or carcinoma in situ of the trachea (D02.1). Using C33 for these presentations would be a coding error with claim rejection implications.

Code hierarchy: Where C33 sits in the ICD-10-CM classification

Understanding the hierarchical position of C33 helps coders quickly navigate related codes and spot the correct level of specificity. The CDC/NCHS ICD-10-CM web tool shows the full hierarchy from chapter down to code:

Because C33 has no subcategories, it is a category-level code that is also the final, billable code. Coders do not need to search for a five-character extension: C33 itself is the most specific code available in ICD-10-CM for primary tracheal malignancy.

Related ICD-10-CM codes in the C30-C39 range

The C30-C39 block covers the full spectrum of respiratory and intrathoracic malignancies. Knowing adjacent codes reduces the risk of miscoding tracheal cancer as a bronchial or laryngeal tumor, which is the most frequent documentation error in this region. Consult the AAPC ICD-10-CM code lookup for full code descriptions and coding notes for each code below.

How C33 differs from C34 (malignant neoplasm of bronchus and lung)

The C33 versus C34 distinction is the single most common tracheal cancer ICD-10 coding error. Both codes cover primary airway malignancies, but the anatomical boundary is clear: the trachea ends at the carina, the bifurcation point where the left and right main bronchi begin.

Any malignancy arising below the carina is a bronchial or pulmonary malignancy, coded to C34 with a mandatory laterality extension.

Clinicians should document whether the tumor originates above or at the carina (tracheal = C33) or below it (bronchial/pulmonary = C34.-). When pathology or imaging confirms tracheal origin but the report uses vague language such as “lower airway malignancy,” query the physician before assigning C34 by default.

Precise documentation in structured patient records prevents this mis-assignment at the point of care.

Coding guidelines and documentation requirements for ICD-10 code C33

Accurate ICD-10 code C33 assignment requires supporting documentation that satisfies both clinical and payer requirements. The following guidelines are drawn from the ICD-10-CM Official Guidelines for Coding and Reporting, maintained by the National Center for Health Statistics (NCHS) and the Centers for Medicare and Medicaid Services (CMS).

• Primary site confirmation: The physician or pathology report must explicitly state that the malignancy originates in the trachea, not that it involves or extends to the trachea from an adjacent site.
• Histology codes: Assign a morphology code (from ICD-O-3 or the neoplasm table) alongside C33 when histological type is known. Squamous cell carcinoma and adenoid cystic carcinoma are the predominant histological subtypes.
• Additional codes for manifestations: Code separately any functional activity, associated conditions, or treatment complications. For example, M36.1 applies when neoplasm-related arthropathy is also documented. If the patient is receiving chemotherapy or radiation, add a code from the Z51.- series (encounter for antineoplastic therapy) and reference the treatment note, such as a cytarabine administration note, that documents the specific agent given.
• Tobacco exposure and use codes: ICD-10-CM attaches a “use additional code” note to C33 for tobacco-related exposure or dependence, when documented, such as Z87.891 (personal history of nicotine dependence) or a code from the F17.- category. Assign these only when the record supports them.
• Sequencing for inpatient: When the malignant neoplasm of trachea is the condition established after study to be chiefly responsible for the admission, sequence C33 as the principal diagnosis.
• Personal history after treatment: Once the cancer is considered treated and no longer present, replace C33 with Z85.12 (personal history of malignant neoplasm of trachea) or the appropriate personal-history neoplasm code.

Present on admission (POA) indicator for C33

For inpatient hospital claims submitted to Medicare and Medicaid, the POA indicator is required for all diagnosis codes on the claim. C33 is not a POA-exempt code: coders must assign one of the standard POA indicators (Y, N, U, W, or 1) based on the attending physician’s documentation.

The correct indicator for most tracheal cancer admissions will be “Y” (present on admission), since the diagnosis typically precedes hospitalization. However, if the malignancy is discovered incidentally during an inpatient stay for an unrelated condition, “N” (not present on admission) may apply. When documentation is unclear, query the physician rather than defaulting to “U” (documentation insufficient).

For coders managing medical coding compliance requirements across multiple payers, whether in a thoracic oncology practice or a dermatology group running on dermatology EMR software, verifying POA at the time of coding, not at final bill, reduces downstream audit risk.

MS-DRG assignment and reimbursement mapping

When C33 is assigned as the principal diagnosis on an inpatient claim, CMS’s Medicare Severity Diagnosis Related Group (MS-DRG) grouper determines the facility reimbursement rate. The specific MS-DRG assigned depends on whether significant surgical procedures were performed during the hospitalization and whether the patient had a complication or comorbidity (CC) or major complication or comorbidity (MCC).

C33 typically maps to one of two MS-DRG groupings, depending on whether a significant surgical procedure was performed during the stay. According to the CMS ICD-10-CM/PCS MS-DRG Definitions Manual, MS-DRG 163-165 (Major Chest Procedures, with MCC, with CC, or without CC/MCC) applies when the hospitalization includes a significant chest or tracheal surgical procedure.

MS-DRG 180-182 (Respiratory Neoplasms, with MCC, with CC, or without CC/MCC) applies instead when C33 is the principal diagnosis and no major operating-room procedure was performed. Always validate against the current CMS IPPS grouper tables, since MS-DRG mappings are updated annually.

Facility coders should review the practice management software their organization uses to confirm it incorporates the current-year CMS grouper tables. An outdated grouper can assign a lower-weighted DRG and result in significant underpayment for complex tracheal resection cases.

Reduce claim denials with built-in ICD-10 validation

Pabau's claims management tools validate diagnostic codes against payer rules at the point of entry, so coding errors like C33 versus C34 mis-assignments get caught before the claim is submitted, not after it is denied.

Book a demo

ICD-9-CM crosswalk for C33

Practices still reconciling legacy records or working with payers that reference older data will need the ICD-9-CM equivalent for C33. The General Equivalence Mappings (GEMs) crosswalk, maintained by CMS and NCHS, provides the following mapping:

The GEMs crosswalk is approximate, not exact. ICD-9-CM code 162.0 was the direct predecessor to C33 and covers the same clinical entity, primary malignant neoplasm of trachea. No combinability concerns or partial mappings apply, making this a straightforward one-to-one forward conversion, the same kind of direct mapping coders rely on for other single, non-further-specified codes like B64.

How practice management software handles C33 coding

Most tracheal cancer cases pass through oncology, thoracic surgery, or pulmonology practices, though the primary care practice that orders the first chest imaging, whether it runs on gp-software or a comparable system, shapes how clearly that early referral describes the tumor’s location.

Each specialty that goes on to manage the case faces the same risk: a single coding error, such as using C33 when the mass is below the carina and should carry C34, can trigger an automatic claim rejection or a Medicare audit. Modern claims management software addresses this at the workflow level rather than relying solely on coder knowledge.

Specifically, a well-configured patient management workflow should do three things for C33 claims:

1. Code validation at entry: Flag C33 if accompanying procedure codes suggest a bronchial or pulmonary site, prompting the coder to confirm the anatomical origin before the claim moves to the billing queue.
2. Payer rule checks: Surface any payer-specific Local Coverage Determinations (LCDs) or National Coverage Determinations (NCDs) that attach conditions to C33 reimbursement, such as required staging documentation or prior authorization for certain surgical approaches.
3. Documentation linkage: Connect the diagnosis code to the supporting clinical note so auditors can trace C33 directly to the physician’s documented statement of primary tracheal origin.

Pabau’s EHR and EMR software integrates diagnosis coding into the patient record workflow, so the clinician’s documented site of origin is captured at the consult and flows through to the claim without a manual re-keying step.

For thoracic practices handling rare malignancies like tracheal cancer, that linkage between the diagnosis and the supporting operative note, including the anesthesia record for a procedure like 00474, is what separates clean claims from denial-heavy billing cycles.

Conclusion

Tracheal cancer is rare, but coding it incorrectly is surprisingly common. The carina is the critical anatomical line: primary malignancies above it are C33, and anything below it belongs to the C34 range with mandatory laterality. Getting that distinction documented clearly in the clinical note is the single most effective step a practice can take to prevent denials.

Pabau’s claims management software validates ICD-10-CM codes against procedure codes and payer rules at the point of entry, catching C33 versus C34 mis-assignments before submission. To see how Pabau handles diagnostic code validation across respiratory oncology and other complex billing workflows, book a demo.

Continue your research

Wondering how ICD-10-CM handles a code with no further subdivisions? M30.2 walks through when a parent code stays non-billable and a child code takes over.

Coding an oncology-related surgical claim? 00404 covers anesthesia documentation for a comparable major chest and breast oncology procedure.

Need the billing rules for a chemotherapy agent used in respiratory cancers? J9264 covers dosage units and reimbursement for paclitaxel protein-bound.

Frequently asked questions